These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 9302194)

  • 41. Further development of a new transgenic mouse test for the evaluation of the immunogenicity and protective properties of inactivated poliovirus vaccine.
    Dragunsky EM; Ivanov AP; Abe S; Potapova SG; Enterline JC; Hashizume S; Chumakov KM
    J Infect Dis; 2006 Sep; 194(6):804-7. PubMed ID: 16941347
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunogenicity, safety, and antibody persistence at 3, 5, and 10 years postvaccination in adolescents randomized to booster immunization with a combined tetanus, diphtheria, 5-component acellular pertussis, and inactivated poliomyelitis vaccine administered with a hepatitis B virus vaccine concurrently or 1 month apart.
    Embree J; Law B; Voloshen T; Tomovici A
    Clin Vaccine Immunol; 2015 Mar; 22(3):282-90. PubMed ID: 25540274
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses.
    Faden H; Modlin JF; Thoms ML; McBean AM; Ferdon MB; Ogra PL
    J Infect Dis; 1990 Dec; 162(6):1291-7. PubMed ID: 2172403
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunogenicity and safety of three aluminium hydroxide adjuvanted vaccines with reduced doses of inactivated polio vaccine (IPV-Al) compared with standard IPV in young infants in the Dominican Republic: a phase 2, non-inferiority, observer-blinded, randomised, and controlled dose investigation trial.
    Rivera L; Pedersen RS; Peña L; Olsen KJ; Andreasen LV; Kromann I; Nielsen PI; Sørensen C; Dietrich J; Bandyopadhyay AS; Thierry-Carstensen B
    Lancet Infect Dis; 2017 Jul; 17(7):745-753. PubMed ID: 28454674
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of serum and salivary antibodies in children vaccinated with oral live or parenteral inactivated poliovirus vaccines of different antigen concentrations.
    Zaman S; Carlsson B; Jalil F; Mellander L; Van Wezel AL; Böttiger M; Hanson LA
    Acta Paediatr Scand; 1991 Dec; 80(12):1166-73. PubMed ID: 1785289
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Serum and mucosal antibody responses to inactivated polio vaccine after sublingual immunization using a thermoresponsive gel delivery system.
    White JA; Blum JS; Hosken NA; Marshak JO; Duncan L; Zhu C; Norton EB; Clements JD; Koelle DM; Chen D; Weldon WC; Oberste MS; Lal M
    Hum Vaccin Immunother; 2014; 10(12):3611-21. PubMed ID: 25483682
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Poliovirus Type 2 Seroprevalence Following Full- or Fractional-Dose Inactivated Poliovirus Vaccine in the Period After Sabin Type 2 Withdrawal in Sri Lanka.
    Gamage D; Mach O; Ginige S; Weldon WC; Oberste MS; Jeyaseelan V; Sutter RW
    J Infect Dis; 2019 May; 219(12):1887-1892. PubMed ID: 30649505
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Risk of introduction and spread of polioviruses in closed-type child-care facilities].
    Romanenkova NI; Bichurina MA; Rozaeva NP; Kanaeva OI
    Zh Mikrobiol Epidemiol Immunobiol; 2014; (6):90-5. PubMed ID: 25816521
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lack of immune interference between inactivated polio vaccine and inactivated rotavirus vaccine co-administered by intramuscular injection in two animal species.
    Wang Y; Zade J; Moon SS; Weldon W; Pisal SS; Glass RI; Dhere RM; Jiang B
    Vaccine; 2019 Jan; 37(5):698-704. PubMed ID: 30626530
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety and immunogenicity of a booster dose of inactivated poliovirus vaccine produced in vero-cells.
    Haastrup E; Thierry-Carstensen B; Jensen AM; Stellfeld M; Heilmann C
    Vaccine; 2004 Feb; 22(8):958-62. PubMed ID: 15161072
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sequential and combined use of inactivated and oral poliovirus vaccines: Dolj District, Romania, 1992-1994.
    Ion-Nedelcu N; Strebel PM; Toma F; Biberi-Moroeanu S; Combiescu M; Persu A; Aubert-Combiescu A; Plotkin SA; Sutter RW
    J Infect Dis; 1997 Feb; 175 Suppl 1():S241-6. PubMed ID: 9203723
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect on seroprevalence of anti-poliovirus antibodies and on vaccination coverage of the implementation of a DTwP-IPV-Hib vaccination programme in a South American city.
    Nates SV; Frias M; Belfiore S; Isa MB; Martinez LC; Chuit R; Armoni J; Luxemburger C
    Epidemiol Infect; 2011 Jun; 139(6):826-35. PubMed ID: 20587121
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Newcastle Disease Virus-Based Vectored Vaccine against Poliomyelitis.
    Viktorova EG; Khattar SK; Kouiavskaia D; Laassri M; Zagorodnyaya T; Dragunsky E; Samal S; Chumakov K; Belov GA
    J Virol; 2018 Sep; 92(17):. PubMed ID: 29925653
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial.
    Asturias EJ; Bandyopadhyay AS; Self S; Rivera L; Saez-Llorens X; Lopez E; Melgar M; Gaensbauer JT; Weldon WC; Oberste MS; Borate BR; Gast C; Clemens R; Orenstein W; O'Ryan G M; Jimeno J; Clemens SA; Ward J; Rüttimann R;
    Lancet; 2016 Jul; 388(10040):158-69. PubMed ID: 27212429
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antibody response and viral excretion after live polio vaccine or a combined schedule of live and inactivated polio vaccines.
    Ramsay ME; Begg NT; Gandhi J; Brown D
    Pediatr Infect Dis J; 1994 Dec; 13(12):1117-21. PubMed ID: 7892081
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunogenicity and reactogenicity of a decennial booster dose of a combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and inactivated poliovirus booster vaccine (dTpa-IPV) in healthy adults.
    Kovac M; Rathi N; Kuriyakose S; Hardt K; Schwarz TF
    Vaccine; 2015 May; 33(22):2594-601. PubMed ID: 25882172
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of immunogenicity and protective properties of inactivated poliovirus vaccines: a new surrogate method for predicting vaccine efficacy.
    Dragunsky EM; Ivanov AP; Wells VR; Ivshina AV; Rezapkin GV; Abe S; Potapova SG; Enterline JC; Hashizume S; Chumakov KM
    J Infect Dis; 2004 Oct; 190(8):1404-12. PubMed ID: 15378432
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [VACCINE-ASSOCIATED PARALYTIC POLIOMYELITIS IN RUSSIAN FEDERATION DURING THE PERIOD OF CHANGES IN VACCINATION SCHEDULE (2006-2013 yy.)].
    Ivanova OE; Eremeeva TP; Morozova NS; Shakaryan AK; Gmyl AP; Yakovenko ML; Korotkova EA; Chernjavskaja OP; Baykova OY; Silenova OV; Krasota AY; Krasnoproshina LI; Mustafina AN; Kozlovskaja LI
    Vopr Virusol; 2016; 61(1):9-15. PubMed ID: 27145594
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Priming after a fractional dose of inactivated poliovirus vaccine.
    Resik S; Tejeda A; Sutter RW; Diaz M; Sarmiento L; Alemañi N; Garcia G; Fonseca M; Hung LH; Kahn AL; Burton A; Landaverde JM; Aylward RB
    N Engl J Med; 2013 Jan; 368(5):416-24. PubMed ID: 23363495
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Elimination of poliomyelitis in Finland.
    Lapinleimu K
    Rev Infect Dis; 1984; 6 Suppl 2():S457-60. PubMed ID: 6330841
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.